Richard Scott Struthers - 04 Mar 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
04 Mar 2024
Transactions value $
$0
Form type
4
Filing time
06 Mar 2024, 20:01:02 UTC
Previous filing
14 Feb 2024
Next filing
20 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +65K +35.04% $0.00 251K 04 Mar 2024 Direct F1
holding CRNX Common Stock 571K 04 Mar 2024 By Family Trust 1
holding CRNX Common Stock 110K 04 Mar 2024 By Family Trust 2
holding CRNX Common Stock 110K 04 Mar 2024 By Family Trust 3
holding CRNX Common Stock 110K 04 Mar 2024 By Family Trust 4
holding CRNX Common Stock 1K 04 Mar 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Award $0 +240K $0.00 240K 04 Mar 2024 Common Stock 240K $43.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025.
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024.